<DOC>
	<DOCNO>NCT02027012</DOCNO>
	<brief_summary>REDUCE-HTN-China study prospective , multi-center , single cohort study percutaneous therapeutic treatment medication-resistant hypertension China.The primary objective ass efficacy performance Vessix™ Renal Denervation System treatment medication resistant hypertension basis hypothesis percutaneous therapeutic renal denervation treatment medication-resistant hypertension use Vessix™ Renal Denervation System reduce systolic ( SBP ) diastolic blood pressure ( DBP ) 6- month compare baseline access office-based blood pressure measurement .</brief_summary>
	<brief_title>Treatment Resistant Hypertension Renal Denervation China</brief_title>
	<detailed_description>The Vessix System highly-differentiated advance renal denervation system feature intuitive push-button interface , short 30-second treatment time over-the-wire , balloon-based approach familiar cardiac vascular specialist . The Vessix System CE Mark TGA approval currently available sale Europe , Middle East , Australia , New Zealand select market Asia . The Vessix System investigational device available sale China . An current analysis REDUCE-HTN post market study affirm device 's safety profile effective treatment resistant hypertension .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Have provide write informed consent Are ≥ 18 year ≤ 75 year age Have SBP /DBP ≥ 160/90 mm Hg base average three officebased blood pressure reading ( seat ) measure accord protocol ( ≥ 150 mmHg subject Type 2 diabetes ) On stable medication regimen ≥ 3 antihypertensive drug ( one medication diuretic , unless subject document intolerance diuretic ) maximally tolerate dos change medication regimen two ( 2 ) week prior enrollment With eGFR ≥ 40 ml/min per 1.73m² Are willing able comply study procedure With main renal artery diameter ≥ 3.5 mm ≤ 7.0 mm kidney With main renal artery without significant stenosis ( stenosis define &lt; 30 % ) With renal artery length ≥ 15 mm With secondary hypertension With Type I Diabetes Mellitus Are contraindicate intravascular contrast material Are contraindicate anticoagulation medication ( heparin , aspirin , Angiomax , etc . ) , analgesic medication ( morphine , fentanyl , etc . ) , anxiolytic medication ( alprazolam , lorazepam , diazepam , etc . ) medication require interventional procedure With known bleed hypercoagulation disorder Have experience myocardial infarction , unstable angina pectoris , uncompensated heart failure , cerebrovascular accident within six ( 6 ) month prior screen visit , widespread atherosclerosis , document intravascular thrombosis unstable plaque Have plan percutaneous vascular surgical intervention reason within next 6 month Have hemodynamically significant valvular heart disease reduction blood pressure would consider hazardous Have implantable cardioverter defibrillator ( ICD ) pacemaker clinically significant abnormal electrocardiogram time screen Have serious medical condition , opinion investigator , may adversely affect subject safety efficacy procedure study ( i.e. , subject clinically significant peripheral vascular disease , abdominal aortic aneurysm , bleed disorder ) Are pregnant , nurse plan become pregnant currently take estrogen estrogenlike compound ( female participant childbearing potential must negative serum urine human chorionic gonadotropin ( hCG ) pregnancy test prior procedure ) Have know , unresolved history drug use alcohol abuse/dependency Are currently enrol investigational study wherein subject participation complete For reason , may able understand comply instruction With one kidney With prior renal denervation procedure With prior intervention right leave renal artery With renal artery stenosis define ≥ 30 % stenosis confirm angiography two ( 2 ) orthogonal view selective catheterization With iliac stenosis require intervention time procedure and/or within next six ( 6 ) month With severe femoral , renal , iliac aortic calcification may cause potential complication time procedure The physician unable cannulate renal artery The physician unable access femoral artery percutaneous mean</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>